The Company received the voucher in February 2021 under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. BridgeBio was awarded the voucher when its affiliate, Origin Biosciences Inc., received approval of NULIBRY™ (fosdenopterin) for injection as the first therapy to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A. The sale is subject to customary closing conditions and is expected to occur following the expiration of applicable U.S. antitrust clearance requirements.
History.htm
Recent BBIO News
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 04/07/2024 05:15:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 10:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:13:04 PM
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 03/06/2024 04:53:56 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 10:25:14 PM
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/04/2024 09:17:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:00:28 PM
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM • GlobeNewswire Inc. • 03/04/2024 07:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:27:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:31:59 PM
- BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update • GlobeNewswire Inc. • 02/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:04:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/20/2024 09:03:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 09:06:39 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:05:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 09:00:10 PM
- BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan • GlobeNewswire Inc. • 02/07/2024 12:34:22 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/06/2024 12:30:00 PM
- BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 02/05/2024 12:30:00 PM
- BridgeBio Pharma Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months • GlobeNewswire Inc. • 02/02/2024 12:00:00 PM
- Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics • PR Newswire (US) • 01/30/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 12:30:19 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM